As ESR1 activating hotspot mutations are reported enriched in endocrine‐resistant metastatic breast tumors (Toy et al., 2013), we tested for any of the helix 12 activating hotspot mutations in 11 randomly selected samples from adjuvant tamoxifen‐treated patients (Fig. S1). This evidence concerns the gene ESR1 and breast neoplasm.